Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program

scientific article published on May 2007

Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/S0828-282X(07)70785-7
P932PMC publication ID2650666
P698PubMed publication ID17487291

P50authorJoanne M. LangleyQ42178451
P2093author name stringAndrew Warren
Jeff Scott
Wanda Thomas
P2860cites workPalivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infectionQ35788059
Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in CanadaQ35792916
Palivizumab use among children with congenital heart disease in Quebec: Impact of Canadian guidelines on clinical practice.Q36731851
Impact of respiratory syncytial virus infection on surgery for congenital heart disease: postoperative course and outcomeQ43673006
Prophylaxis against respiratory syncytial virus (RSV), varicella, and pneumococcal infections: economic-based decision-makingQ45709923
Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart diseaseQ45710733
Respiratory syncytial virus in patients with congenital heart disease: a contemporary look at epidemiology and success of preoperative screeningQ45740689
Economic analysis of palivizumab in infants with congenital heart diseaseQ47886680
Increasing incidence of hospitalization for bronchiolitis among Canadian children, 1980-2000.Q51641779
Statement on the recommended use of monoclonal anti-RSV antibody (palivizumab)Q51650931
Use of palivizumab in children with congenital heart diseaseQ82284318
P433issue6
P921main subjectcongenital disorderQ727096
congenital heart diseaseQ939364
P304page(s)463-466
P577publication date2007-05-01
P1433published inThe Canadian Journal of CardiologyQ3502278
P1476titleOptimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program
P478volume23

Reverse relations

cites work (P2860)
Q42226322Increased risk of RSV infection in children with Down's syndrome: clinical implementation of prophylaxis in the European Union
Q33593708Respiratory Watch: Development of a provincial system for respiratory syncytial virus surveillance in Nova Scotia, 2005-2008.

Search more.